Galapagos NV (GLPG) has been beaten down lately with too much selling pressure. While the stock has lost 7.9% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. ☐ Item 17 ...

EXHIBIT 99.1 Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 Webcast presentation tomorrow, 3 November 2023, at 13:00 CET / 8:00 am ET, www.glpg.com Mechelen, Belgium; 2 November 2023, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its financial results for the first nine months of 2023, a year-to-date business update and its outlook for the remainder of 2023. "We continue to be very enc ...

Thad Huston On today's call, Thad will present the operational and financial section. Thad? Galapagos NV (NASDAQ:GLPG) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commercial Officer Daniele D'Ambrosio - Head of Immunology Conference Call Participants I would like to remind everyone that we will be making forward-looking statements during today's webc ...

Galapagos NV (NASDAQ:GLPG) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paulus Stoffels - CEO, Chairman, Interim Head, R&D Bart Filius - President, COO & CFO Michele Manto - Chief Commercial Officer Conference Call Participants Michael Ulz - Morgan Stanley Peter Verdult - Citigroup Dane Leone - Raymond James & Associates Jason Gerberry - Bank of America Merrill Lynch Brian Balchin - Jefferies Operator Good day, and thank you for standing by. Welcom ...

Strategic Collaboration - Galapagos NV and NovAliX announced a strategic collaboration involving the transfer of Galapagos' drug discovery and research activities in Romainville, France[2]. - The collaboration is part of Galapagos' strategic reorientation towards a fit-for-purpose R&D organization, focusing on oncology and immunology[2]. - The collaboration aims to accelerate innovation, reduce risks, and shorten drug development timelines[2]. - The strategic partnership reflects the evolving landscape of the biopharmaceutical industry, emphasizing new collaboration models between CROs and biopharmaceutical companies[4]. Financial Impact - The financial impact of the transaction is included in Galapagos' previously announced 2023 cash burn guidance, estimated to be between €380 million and €420 million[3]. - The transaction is expected to close in July 2023, subject to customary closing conditions[3]. Drug Discovery Enhancement - The acquisition will allow NovAliX to enhance its drug discovery capabilities, particularly in kidney diseases, fibrosis, and immunology, complementing its existing expertise in oncology and infectious diseases[4]. - NovAliX's acquisition includes a highly skilled team from Galapagos, enhancing its DNA-Encoded Libraries database and cryo-EM driven discovery engine[4]. - Galapagos retains the flexibility to access NovAliX's research capabilities through a five-year collaboration agreement[6]. Commitment to Medical Needs - Galapagos' first medicine for rheumatoid arthritis and ulcerative colitis is already available in Europe and Japan, indicating its commitment to addressing high unmet medical needs[5].

Product Dependence - The company reported a significant reliance on the success of filgotinib, which is approved for rheumatoid arthritis and ulcerative colitis in the EU, Great Britain, and Japan, marketed under the brand name Jyseleca[23]. - The company is heavily dependent on its global R&D collaboration with Gilead for the commercialization and development of filgotinib, with no assurance of expected benefits[20]. Financial Challenges - The company has no historical profit from product sales, making it challenging to assess future prospects and financial results[21]. - The company is prioritizing the development of certain product candidates due to limited resources and access to capital[26]. - The company may be subject to ongoing regulatory obligations and reviews, resulting in significant additional expenses if product candidates are approved[29]. Market and Competition - The company faces significant competition in drug discovery and development, which could reduce or eliminate commercial opportunities[31]. - The regulatory approval processes for product candidates are lengthy and unpredictable, which may affect commercial viability[27]. Investment and Infrastructure - The company is investing in building its marketing and sales capabilities to establish a European commercial infrastructure[22]. Market Risks - The market price of the company's American Depositary Shares (ADSs) could experience wide fluctuations[33]. - The company may face increased risks of securities class action litigation[34].

EXHIBIT 99.1 Galapagos increases share capital through subscription right exercises Mechelen, Belgium; 20 March 2023, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 61,560 new ordinary shares on 20 March 2023, for a total capital increase (including issuance premium) of EUR 1,769,850.00. In accordance with Belgian transparency legislation, Galapagos also wishes to note that its total sha ...

Galapagos NV (NASDAQ:GLPG) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D’Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voo ...

Galapagos NV (NASDAQ:GLPG) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid Abi-Saab - Chief Medical Officer Michele Manto - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Jason Gerberry - Bank of America Charlie Mabbutt - Bernstein James Gordon - JPMorgan Matthew Harri ...